08:35 AM EDT, 08/03/2026 (MT Newswires) -- Cizzle Biotechnology Holdings' (CIZ.L) Cizzle Bio signed an agreement with US-based healthcare services organization BioBridge Global to support the rollout of its CIZ1B biomarker blood test for lung cancer. BioBridge's BBG Advanced Therapies subsidiary will offer the test to licensed healthcare providers across South Texas, the US, once it secures the relevant certification as a laboratory partner, according to a Monday release. The commercial agreement executed by the early-stage cancer diagnostic tests company's North American licensing partner, its second with a clinical laboratory group, aims to accelerate the sales of the tests in the US.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.